Form 4: MAIA Biotechnology Director Acquires Stock Options
SEC Form 4 Filing
Jean-Manasse Theagene, a director of MAIA Biotechnology, Inc., acquired 9,193 stock options on March 31, 2024.
Summary
- On March 31, 2024, Jean-Manasse Theagene, a director of MAIA Biotechnology, Inc., acquired 9,193 stock options.
- The stock options were granted pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan.
- The options vest immediately and are exercisable from the grant date.
- The exercise price of the options is $2.20.
- The options expire on March 31, 2034.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to stock option grants. It doesn't inherently convey positive or negative sentiment, but the director's acquisition of options could be interpreted as a mildly positive signal.
Positives
- The director's acquisition of stock options could be seen as a positive sign, indicating confidence in the company's future prospects.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director could potentially impact shareholder sentiment, depending on how it's perceived.
Key Dates
| Date | Description |
|---|---|
| 03/31/2024 | Date of transaction: Director acquired stock options. |
| 03/31/2024 | Date options vest and become exercisable. |
| 03/31/2034 | Expiration date of the stock options. |
| 04/02/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.